A novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development, and the genetics of NAFLD
Posted 27th March 2019 by Joshua Broomfield
Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available.
The Burden Of NASH
Posted 21st December 2018 by Jane Williams
The burden of non-alcoholic fatty liver disease (NAFLD) continues to increase at an alarming rate. The prevalence of disease equals the prevalence of metabolic syndrome (nearly 30% of the adult population), and NASH-cirrhosis represents the second cause for entering the waiting list for liver transplantation, with/without associated primary liver cancer.
Lipids versus hepatic inflammation: a lysosomal interplay
Posted 7th December 2018 by Jane Williams
The consumption of a healthy diet in combination with regular physical exercise is essential for an optimal and healthy condition, keeping the body in good shape. Although dietary guidelines may help in defining what is a healthy diet, the term healthy not only depends on individual needs and/or opinions.
Is Not Dying Yet on your bucket list?
Posted 30th November 2018 by Jane Williams
The Fatty Liver Foundation exists because I was not willing to be a well behaved member of the parade of misery that liver disease is becoming for our society. My bucket list includes not dying of liver disease.
The need for non-invasive diagnosis and monitoring of NASH
Posted 29th October 2018 by Jane Williams
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease and is increasing in prevalence as an etiology for end-stage liver disease and also hepatocellular carcinoma. NASH is often a silent disease and many patients have undiagnosed NASH for several years without experiencing any symptoms.
The race to find a treatment for NASH; what’s the big hold up?
Posted 12th June 2018 by Jane Williams
If I were to tell you that there was a multi-million pound race to help more than 1 billion people – you would call me crazy, but believe it or not, it’s actually true! In recognition of International NASH Day, I’m asking what’s the big hold up when it comes to treating NASH?
The Global NASH Congress – Slide release
Posted 23rd May 2018 by Jane Williams
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
Over the course of the Global NASH Congress, 40 expert-led presentations and interactive roundtable discussions explored these key issues. If you were unable to attend, please enjoy these free slides from Eric Hughes, Jon Reik and Pierre Bedossa.
NASH – The Silent Killer You’ve Never Heard Of
Posted 12th February 2018 by Jane Williams
Silent killers such as diabetes, high cholesterol and hypertension have been well discussed for many years. While non-medical professionals may not understand the pathophysiology of these diseases, most people can appreciate that they are harmful conditions which require treatment. Worldwide, nonalcoholic fatty liver disease (NAFLD) is estimated to affect more than 1 billion people; so why is nobody talking about it?
